Enliven Therapeutics Inc Stock Performance
as on October 23, 2025 at 1:29 am IST
Day's Low
Day's High
$20.11$21.19
1.71%
Downside
3.57%
Upside
52 Week's Low
52 Week's High
$13.3$29.7935.00%
Downside
45.58%
Upside
Enliven Therapeutics Inc share price movements today
- Previous Close
- $21.19
- Open
- $21.14
- Volume
- 292.6K
- Day's Low - High
- $20.11 - $21.19
- 52 Week Low - High
- $13.3 - $29.79
Enliven Therapeutics Inc Historical Returns
- 1 Month Return
- + 6.38 %
- 3 Month Return
- -1.72 %
- 1 Year Return
- -26.88 %
- 3 Year Return
- 0 %
- 5 Year Return
- 0 %
Enliven Therapeutics Inc Stock Fundamentals & Key Indicators
Check Enliven Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.3B
EPS (TTM)
-1.59
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-113.9M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
68968500.00%
Enliven Therapeutics Inc vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Enliven Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $1.3B | NA | NA | 0.00% | |
| BUY | $64.4B | 252.94% | -505.15 | -12.96% | |
| NA | $35.3B | NA | NA | -3.89% | |
| BUY | $107.5B | 102.91% | 29.68 | 31.86% | |
| BUY | $61.3B | 0.63% | 14.58 | 31.37% |
Stock Returns calculator for Enliven Therapeutics Inc Stock including INR - Dollar returns
The Enliven Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Enliven Therapeutics Inc investment value today
Current value as on today
₹75,158
Returns
Returns from Enliven Therapeutics Inc Stock
Dollar Returns*
₹4,557 (+4.56%)
Analyst Recommendation on Enliven Therapeutics Inc Stock
Based on 10 analysts
90.00%
Buy
10.00%
Hold
0.00%
Sell
Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Enliven Therapeutics Inc. Average target price of $41.25
Enliven Therapeutics Inc Share Price Target
Get share price movements and forecasts by analysts on Enliven Therapeutics Inc.
What analysts predicted
50.4%UPSIDE
Target Price
$41.25
Current Price
$20.46
Analyzed by
10 Analysts
Target
$41.25
Enliven Therapeutics Inc target price $41.25, a slight upside of 50.4% compared to current price of $20.46. According to 10 analysts rating.
Enliven Therapeutics Inc Stock’s Investor Sentiment and Interest
Search interest for Enliven Therapeutics Inc Stock has increased by 200% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:200% versus previous 30 day period
Enliven Therapeutics Inc Quarterly Profit & Loss
All numbers in Millions USD
Enliven Therapeutics Inc Annual Profit & Loss
All numbers in Millions USD
Enliven Therapeutics Inc Quarterly Cash Flow
All numbers in Millions USD
Enliven Therapeutics Inc Annual Cash Flow
All numbers in Millions USD
Insights on Enliven Therapeutics Inc
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
NO EFFECTAgainst Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.7% return, outperforming this stock by 87.6%
NEGATIVE IMPACTPrice Dip
In the last 7 days, ELVN stock has moved down by -2.6%
About Enliven Therapeutics Inc
| Organisation | Enliven Therapeutics Inc |
| Headquarters | 6200 Lookout Road, Boulder, CO, United States, 80301 |
| CEO | Mr. Samuel S. Kintz M.B.A. |
| E-voting on shares | Click here to vote |
Key Management of Enliven Therapeutics Inc
Name | Title |
|---|---|
Mr. Benjamin Hohl | CFO & Head of Corporate Development |
Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development |
Mr. Samuel S. Kintz M.B.A. | Co-Founder, CEO, Secretary & Director |
Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer |
Dr. Helen Louise Collins M.D. | Chief Medical Officer |
Mr. Anish Patel Pharm.D. | Co-Founder & COO |
FAQs
What is Enliven Therapeutics Inc share price today?
Enliven Therapeutics Inc share price today is $20.46 as on at the close of the market. Enliven Therapeutics Inc share today touched a day high of $21.19 and a low of $20.11.
What is the 52 week high and 52 week low for Enliven Therapeutics Inc share?
Enliven Therapeutics Inc share touched a 52 week high of $29.79 on and a 52 week low of $13.3 on . Enliven Therapeutics Inc stock price today i.e. is closed at $20.46,which is 31.31% down from its 52 week high and 53.83% up from its 52 week low.
What is Enliven Therapeutics Inc's market capitalisation today?
Enliven Therapeutics Inc market capitalisation is $0.00T as on .
How to invest in Enliven Therapeutics Inc Stock (ELVN) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Enliven Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Enliven Therapeutics Inc Shares that will get you 0.0733 shares as per Enliven Therapeutics Inc share price of $20.46 per share as on October 23, 2025 at 1:29 am IST.
What is the minimum amount required to buy Enliven Therapeutics Inc Stock (ELVN) from India?
Indian investors can start investing in Enliven Therapeutics Inc (ELVN) shares with as little as ₹87.755 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹877.55 in Enliven Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Enliven Therapeutics Inc share’s latest price of $20.46 as on October 23, 2025 at 1:29 am IST, you will get 0.4888 shares of Enliven Therapeutics Inc. Learn more about
fractional shares .